A better biomarker to predict cetuximab response in CRC patients

(InSilico Medicine, Inc.) Scientists at Insilico Medicine, Inc. and Champions Oncology, Inc. have successfully demonstrate a method to predict response to cetuximab in patients with colorectal cancer using OncoFinder pathway activation strength. The study identified a novel prognostic marker in colorectal cancer treated with cetuximab.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news